We are delighted to announce that Anaphylaxis UK has been successful in its application to Innovate UK for funding to set up a Knowledge Transfer Partnership (KTP) with the University of Surrey to offer support that addresses the psychological impact of living with serious allergies.

Thursday, 13 March marks University Mental Health Day. Did you know that 1 in 4 students have a diagnosed mental health issue, and 30% report that their mental health has worsened since starting university? (Student Minds, Feb 2023).  As a

We’re excited to announce that Anaphylaxis UK will be returning to the Allergy & Free From Show on 21-22 June at Olympia London.  

We are proud to announce our new partnership with Royal Life Saving Society UK (RLSS UK). 

A recent study led by researchers at the Icahn School of Medicine at Mount Sinai, New York, has provided encouraging evidence that a supervised, gradual peanut ingestion protocol may help children with a high-threshold peanut allergy increase their tolerance to

Anaphylaxis UK is delighted to be working with NHS Trusts in Gateshead & Newcastle-upon-Tyne on their BeatAnaphylaxis course for schools in the North East. 

The University of Manchester is inviting individuals to participate in an event where they can share their healthcare experiences and contribute to meaningful discussions with student researchers. This research opportunity aims to help students learn directly from patients about their

The National Institute for Health and Care Excellence (NICE) has released its final draft guidance, recommending Acarizax for NHS use in the management of house dust mite allergy. Developed by ALK-Abello, Acarizax is the first therapy specifically designed to treat

ARS Pharmaceuticals has made significant progress in expanding access to neffy®, its needle-free adrenaline (epinephrine) nasal spray. After gaining approval in the U.S. and Europe for treating severe allergic reactions like anaphylaxis, ARS Pharmaceuticals has now filed for approval in